Momenta Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Oncology Drug Candidate M402

Preclinical data for M402, a novel oncology drug candidate being developed by Momenta Pharmaceuticals, Inc.

, showed that M402 in combination with gemcitabine prolonged survival and substantially lowered the incidence of metastasis in two pancreatic cancer models. The data were presented today in a poster presentation at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster presented preclinical data showing the potential of a future clinical approach for the treatment of patients with metastatic pancreatic cancer combining a drug candidate that targets multiple cancer biology pathways with standard of care chemotherapy treatment.